- Helen Thackray, M.D., Appointed Chief Medical Officer; Brian Hahn Named Chief Financial Officer -
GAITHERSBURG, Md.--(BUSINESS WIRE)-- GlycoMimetics, Inc. (GMI), a clinical-stage biotechnology company developing a new class of glycobiology-based therapies for a broad range of indications, today announced that it has promoted Helen Thackray, M.D., to Chief Medical Officer & Vice President of Clinical Development and Brian Hahn to Chief Financial Officer.
“Over the last few years, GlycoMimetics has significantly advanced both our clinical program and our business model, with our lead candidate GMI-1070 now in Phase 2 clinical trials for the treatment of vaso-occlusive crises associated sickle cell disease and under an exclusive worldwide licensing agreement with Pfizer Inc. (NYSE:PFE),” said GlycoMimetics Chief Executive Officer Rachel King. “As we continue to drive the company forward, I am pleased to recognize the contributions of both Helen Thackray and Brian Hahn, who will play critical roles in our future success as CMO and CFO, respectively.”
Helen Thackray, M.D., FAAP, Chief Medical Officer and Vice President of Clinical Development
Dr. Thackray joined GlycoMimetics in 2006. Previously, she was Vice President of Clinical Product Development at Biosynexus, Inc., for five years. While at Biosynexus, Dr. Thackray oversaw the complex clinical development of a biologic product in hospitalized neonates. Concurrent to her position at GlycoMimetics, Dr. Thackray holds an appointment as Assistant Clinical Professor of Pediatrics at the George Washington University School of Medicine and is a practicing board-certified hospital-based pediatrician. Prior to entering industry, she completed a pediatrics residency at Children's National Medical Center in Washington, D.C., followed by a year as Pediatric Chief Resident and Adjunct Instructor in Pediatrics. She served as a Medical Genetics Fellow at the National Human Genome Research Institute of the National Institutes of Health. Dr. Thackray received her B.S. from Stanford University and her M.D. from George Washington University School of Medicine. She is a member of the Institutional Review Board of the National Center for Healthcare Statistics; recently served on the BIO PDUFA V Technical Discussions team; and is a Fellow of the American Academy of Pediatrics.
Brian Hahn, Chief Financial Officer
Mr. Hahn has over 15 years of senior financial and operations experience in emerging organizations. He joined GlycoMimetics in 2010. Previously, Mr. Hahn served as Executive Director of Finance at MiddleBrook Pharmaceuticals (formerly Advancis Pharmaceutical), a publicly traded specialty pharmaceutical company. Prior to Advancis, he was a senior accountant with Bering Truck Corporation. He began his career as an auditor for the Bank of Clarke County. Over the last ten years, Mr. Hahn has worked with life science companies from early stages (including an initial public offering) through product launch. He has broad experience in developing strategic plans, creating business models, establishing accounting and auditing systems, and ensuring Sarbanes-Oxley compliance. Mr. Hahn received a B.B.A. in Accounting from Shenandoah University and an M.B.A. from the University of Maryland.
About GlycoMimetics, Inc.
GlycoMimetics is a privately held biotechnology company that capitalizes on advances in the field of glycobiology. The company uses rational design of small molecule drugs that mimic the functions of bioactive carbohydrates to develop new drug candidates. The company's initial focus is on therapeutics to treat inflammation, cancer, and infectious diseases. For additional information, please visit the company's web site: http://www.glycomimetics.com.
Brian Hahn, 240-243-1207
KEYWORDS: United States North America Maryland
INDUSTRY KEYWORDS: Health Biotechnology Clinical Trials Pharmaceutical Research Science